Robert A. Reed
Geen lopende functies
Loopbaan van Robert A. Reed
Eerdere bekende functies van Robert A. Reed
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
XENOPORT, INC. | Corporate Officer/Principal | 01-01-2009 | 01-01-2009 |
Jefferson-Pilot Corp. | Corporate Officer/Principal | - | 05-04-2006 |
REATA PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | - | - |
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
ARADIGM CORPORATION | Corporate Officer/Principal | 30-04-2015 | - |
IMUNON, INC. | Corporate Officer/Principal | 07-12-2009 | - |
Opleiding van Robert A. Reed
The University of North Carolina at Charlotte | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Operationeel
Corporate Officer/Principal | 5 |
Doctorate Degree | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
Health Technology | 6 |
Finance | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
IMUNON, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Jefferson-Pilot Corp. | Finance |
XenoPort, Inc.
XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Aradigm Corp.
Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
- Beurs
- Insiders
- Robert A. Reed
- Ervaring